New Haven, Connecticut

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Epilepsy2 trials
• Alopecia areata1 trial
• Schizophrenia1 trial

Phase

• Phase 24 trials

Status

• Completed2 trials
• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• AbbVie3 trials
• Q32 Bio Inc.1 trial

Running trials

• Active, not recruiting

  A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

  NCT06018428· Phase 2· Q32 Bio Inc.· Source

Closed trials

• Completed

  A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

  NCT05227703· Phase 2· AbbVie· Source

• Terminated

  An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

  NCT04686786· Phase 2· AbbVie· Source

• Completed

  A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

  NCT04244175· Phase 2· AbbVie· Source